Drug Type Monoclonal antibody |
Synonyms MIL 62, MIL-62 |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glomerulonephritis, Membranous | Phase 3 | CN | 02 Jun 2023 | |
Idiopathic Membranous Glomerulonephritis | Phase 3 | CN | 02 Jun 2023 | |
Systemic Lupus Erythematosus | Phase 3 | CN | 26 May 2023 | |
Neuromyelitis Optica | Phase 3 | CN | 18 Aug 2022 | |
Marginal zone lymphoma refractory | Phase 3 | CN | 02 Jun 2021 | |
Refractory Follicular Lymphoma | Phase 3 | CN | 02 Jun 2021 | |
Lupus Nephritis | Phase 2 | CN | 26 Nov 2021 | |
Myasthenia Gravis | Phase 2 | CN | 27 Sep 2021 | |
B-cell lymphoma recurrent | Phase 2 | CN | 28 Jul 2020 | |
B-cell lymphoma refractory | Phase 2 | CN | 28 Jul 2020 |
Phase 1/2 | 85 | ciprplxsom(cyajmsovbv) = occurred in 16.7%, 0.0% and 8.0% of patients in the MIL62 600 mg, MIL62 1000 mg and Cyclosporine group respectively adtgevmiit (mkixjozfwy ) View more | Positive | 14 Jun 2023 | |||
NCT04304040 (ASH2022) Manual | Phase 1/2 | 43 | qodevnjysd(jyftsuphct) = uiqyheycnm apeatnhoti (wiipnnybew ) View more | Positive | 12 Dec 2022 | ||
Phase 1/2 | 43 | fsofyfdpuj(ypidjcrihn) = MIL62输液反应发生率为11.6%, 均为 1-2级 hkwkenmmzx (xoqmxllqxu ) View more | - | 21 Sep 2022 | |||
NCT04110301 (ASH2021) Manual | Phase 1/2 | 54 | hxntzgswto(sfqvvmnfqp) = gvmznrtmku neujgplubu (dplkxjsjos ) View more | Positive | 05 Nov 2021 | ||
refractory to rituximab | hxntzgswto(sfqvvmnfqp) = ntluvaejvv neujgplubu (dplkxjsjos ) View more | ||||||
NCT04304040 (ESMO2021) Manual | Phase 1/2 | B-cell lymphoma refractory CD20 Positive | 14 | tnctjqlaoz(ignwgnzvdm) = thrombocytopenia (5/14, 35.7%), infusion-related reaction (3/14, 21.4%) and hyperuricemia (3/14, 21.4%) upioajqazt (yvgciivfda ) | Positive | 16 Sep 2021 | |
Phase 1 | 27 | zjbyvxukzr(eairfijwas) = grade 1 infusion-related reaction was observed and experienced with 4 patients yxjxhtjmrr (yzdahhpywg ) View more | Positive | 17 Sep 2020 |